Low-dose chemotherapeutic drugs induce reactive oxygen species and initiate apoptosis-mediated genomic instability

被引:7
作者
Arun, Renganathan [1 ]
Dhivya, Sridaran [1 ]
Abraham, Suresh K. [2 ]
Premkumar, Kumpati [1 ]
机构
[1] Bharathidasan Univ, Sch Basic Med Sci, Dept Biomed Sci, Canc Genet & Nanomed Lab, Tiruchirappalli 620024, Tamil Nadu, India
[2] Jawaharlal Nehru Univ, Sch Life Sci, New Delhi 110067, India
关键词
DNA-DAMAGE; CANCER; ETOPOSIDE; CELLS; THERAPY; PROLIFERATION; MECHANISMS; GENERATION; RESISTANCE; GROWTH;
D O I
10.1039/c5tx00391a
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Prolonged cancer cell survival, acquiring drug resistance, and secondary cancer development despite chemotherapy are the major challenges during cancer treatment, whose underlying mechanism still remains elusive. In this study, low-doses of chemotherapeutic drugs (LDCD) - doxorubicin (DOX), etoposide (ETOP), and busulfan (BUS) were used to ascertain the effect of residual concentrations of drugs on breast cancer cells. Our results showed that exposure to LDCD caused significant induction of ROS, early signs of apoptosis and accumulation of cells in S and G(2)-M phases of the cell cycle in MCF-7 and MDA-MB-231 cell lines. Under drug-free recovery conditions, a decrease in the number of apoptotic cells and an increase in the number of colonies formed were observed. Analysis of the molecular mechanism showed lower expression of cleaved products of caspase 3, 9, PARP and occurrence of DNA strand breaks in recovered cells compared to LDCD-treated cells, suggesting incomplete cell death activation and survival of cells with genomic damage after therapeutic insult. Thus, LDCD induces defective apoptosis in cancer cells allowing a small population of cells to escape from cell cycle check points and survive with accumulated genetic damage that could eventually result in secondary cancers that warrants further studies for better therapeutic strategies.
引用
收藏
页码:547 / 556
页数:10
相关论文
共 46 条
[11]   Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy [J].
Fulda, S. ;
Debatin, K. -M .
ONCOGENE, 2006, 25 (34) :4798-4811
[12]   Protein Dynamics in Drug Combinations: a Linear Superposition of Individual-Drug Responses [J].
Geva-Zatorsky, Naama ;
Dekel, Erez ;
Cohen, Ariel A. ;
Danon, Tamar ;
Cohen, Lydia ;
Alon, Uri .
CELL, 2010, 140 (05) :643-651
[13]   DNA intrastrand cross-link at the 5′-GA-3′ sequence formed by busulfan and its role in the cytotoxic effect [J].
Iwanoto, T ;
Hiraku, Y ;
Oikawa, S ;
Mizutani, H ;
Kojima, M ;
Kawanishi, S .
CANCER SCIENCE, 2004, 95 (05) :454-458
[14]   Induction of apoptosis by cancer chemotherapy [J].
Kaufmann, SH ;
Earnshaw, WC .
EXPERIMENTAL CELL RESEARCH, 2000, 256 (01) :42-49
[15]   Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen - Role of reactive oxygen and nitrogen species [J].
Kotamraju, S ;
Konorev, EA ;
Joseph, J ;
Kalyanaraman, B .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (43) :33585-33592
[16]   Reliable Comet assay measurements for detecting DNA damage induced by ionising radiation and chemicals [J].
Kumaravel, T. S. ;
Jha, Awadhesh N. .
MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS, 2006, 605 (1-2) :7-16
[17]   Mitochondrial superoxide mediates doxorubicin-induced keratinocyte apoptosis through oxidative modification of ERK and Bcl-2 ubiquitination [J].
Luanpitpong, Sudjit ;
Chanvorachote, Pithi ;
Nimmannit, Ubonthip ;
Leonard, Stephen S. ;
Stehlik, Christian ;
Wang, Liying ;
Rojanasakul, Yon .
BIOCHEMICAL PHARMACOLOGY, 2012, 83 (12) :1643-1654
[18]  
Luo G, 2008, CANCER BIOL THER, V7, P970
[19]   A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia [J].
Maddocks, Kami ;
Ruppert, Amy S. ;
Browning, Rebekah ;
Jones, Jeffrey ;
Flynn, Joseph ;
Kefauver, Cheryl ;
Gao, Yue ;
Jiang, Yao ;
Rozewski, Darlene M. ;
Poi, Ming ;
Phelps, Mitch A. ;
Harper, Erica ;
Johnson, Amy J. ;
Byrd, John C. ;
Andritsos, Leslie A. .
LEUKEMIA RESEARCH, 2014, 38 (09) :1025-1029
[20]   A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments [J].
Masui, Kenta ;
Gini, Beatrice ;
Wykosky, Jill ;
Zanca, Ciro ;
Mischel, Paul S. ;
Furnari, Frank B. ;
Cavenee, Webster K. .
CARCINOGENESIS, 2013, 34 (04) :725-738